6976 results for
Refine Your Search
Addressing Inequities in Access to Care for Patients with Hematologic Malignancy: Understanding the Impact of Telehealth Policies in Medicaid
Telehealth could improve access for Medicaid patients with a blood cancer who experience barriers to specialty care, but not all specialists offer it.…
Anushree Vichare
Dr. Vichare’s research investigates the impact of health policies on health equity. Her training as primary care physician and health services researc…
Glycotyping as a novel approach to study leukemia stem cell heterogeneity and function
Leukemia stem cells (LSCs) are highly heterogeneous populations and key contributors to AML progression. Here, I aim to employ heparan sulfate (HS) gl…
Improving outcomes of multiple myeloma using TGF-beta resistant BCMA-targeted CAR T cells
Immunotherapy using chimeric antigen receptor (CAR) T cells, or CARTs for short, holds great promise for improving outcomes and survival of patients w…
Siegfried Janz
Siegfried Janz, MD, DSc, Professor and William G. Schuett, Jr., Multiple Myeloma Endowed Chair directs translational myeloma research at the Division …
Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL
To survive and proliferate lymphoma cells must co-opt normal cells residing the tumor microenvironment. This process results in the suppression of the…
Leandro Cerchietti
Dr. Cerchietti is physician scientist dedicated to translational research in hematology oncology. His lab conduct mechanistic studies on the genetic, …
Harnessing METTL3 inhibition in acute megakaryoblastic leukemia driven by the t(1;22) fusion involving a member of the m6A writer complex
I want to understand how the t(1;22) translocation that involves a member of the m6A writer complex drives acute megakaryoblastic leukemia (AMKL). To …
Manyi Wei
Dr. Manyi Wei gained his B.S. degree at China Pharmaceutical University in Nanjing. Subsequently, he completed his Ph.D. training in Cell Biology at t…
Spatial architecture and malignant cell characterization of nodular lymphocyte-predominant Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma is recognized as a disease entity in a spectrum of related diseases, including T-cell rich B-cell lymp…
Manabu Fujisawa
Dr. Manabu Fujisawa received M.D. from Kyushu University in Fukuoka, Japan. Motivated by the experience as a hematologist having treated many patient …
Catherine Diefenbach
I am a translational lymphoma researcher and associate professor at the NYU Perlmutter Cancer Center (PCC). My research focuses on the relationship be…
T cell Memory in Cure of Diffuse Large B Cell Lymphoma: An Investigation of the Immune Interactome
While many patients with diffuse large B cell lymphoma (DLBCL) are cured with initial treatment, some patients relapse even after multiple therapies, …
The Role of the DNA Sensor AIM2 in B Cell Fate and Function After HCT
Altered B cell homeostasis plays a key role in the development of chronic graft-vs-host-disease (cGVHD) after hematopoietic stem cell transplantation …
Fahmin Basher
Fahmin Basher, MD, PhD completed her bachelor’s degrees in chemical engineering and biological sciences at the University of South Carolina. She then …
John DiPersio
John F. DiPersio MD, PhD is the Golman Professor of Medicine and Director of The Center for Gene and Cellular Immunotherapy at the Washington Universi…
KT1, a novel NK trispecific antibody for the treatment of AML and MDS
New treatments for AML and MDS are urgently needed. We have developed and performed preliminary testing of a novel, patent-protected, trispecific NK c…
Targeting Epigenetics in Myeloid Malignancies
We have a highly collaborative team of investigators, whose goal is to develop novel therapeutic approaches to MDS and AML as well as to improve curre…
Reina Takeda
Reina Takeda, M.D., Ph. D., is a hematologist and currently a Research Fellow in Pediatric Oncology at Dana-Farber Cancer Institute (DFCI). After rece…
Mechanisms of oncogenic transcription in NPM1-mutant myeloid leukemia
NPM1-mutated leukemia is the most common AML in adult and characterized by upregulations of HOXA/B genes and MEIS1. Given the importance of oncogenic …
Therapeutic targeting of AML stem cells 2018
Our SCOR team seeks to fundamentally reinvent the ways in which physicians diagnose and treat acute myeloid leukemia (AML). For over 40 years, AML has…
Development of BET protein bromodomain inhibitors for the treatment of patients with hematologic malignancies
In July 2012, LLS began its partnership with Constellation to support three first-in-human Phase 1 clinical trials for blood cancer patients and the p…